Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen

Contraception

Volumn 83, Issue 1, 2011, Pages 55-61

  Diliberti, Charles E ^a   O'Leary, Christine M ^a   Hendy, Christopher H ^b   Waters, Donald H ^a   Margolis, Marya B ^a  

^a TEVA PHARMACEUTICALS   (Israel)

^b Novum Pharmaceutical Research Services   (United States)

Author keywords

Ethinyl estradiol; Extended regimen oral contraceptive; Hormone accumulation; Levonorgestrel; Pharmacokinetics

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERVENTILATION; MENSTRUATION; NAUSEA; NORMAL HUMAN; ORAL CONTRACEPTION; PATIENT COMPLIANCE; SIDE EFFECT; STEADY STATE;

ADULT; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HALF-LIFE; HUMANS; LEVONORGESTREL; LONGITUDINAL STUDIES; MIDDLE AGED; YOUNG ADULT;

EID: 78649903424     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.06.015     Document Type: Article

References (24)

1. Bachmann G., Sulak P.J., and Sampson-Landers C. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20μg ethinylestradiol and 3 mg drosperinone Contraception 70 2004 191 198
2. Nakajima S.T., Archer D.F., and Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20μg (Loestrin® Fe) Contraception 75 2007 16 22
3. Anderson F.D., Hait H. the Seasonale 301 Study Group A multicenter randomized study of an extended cycle oral contraceptive Contraception 68 2003 89 96
4. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol Contraception 73 2006 229 234
5. Archer D.F., Jensen J.T., and Johnson J.V. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results Contraception 74 2006 439 445
6. The Mircette Study Group An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive Am J Obstet Gynecol 179 1998 S2 8
7. Coffee A.L., Kuehl T.J., Willis S., and Sulak P.J. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen Am J Obstet Gynecol 195 2006 1311 1319
8. Endrikat J., Gerlinger C., and Plettig K. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use Gynecol Endocrinol 17 2003 107 114
9. Schlaff W.D., Lynch A.M., Hughes H.D., Cedars M.I., and Smith D.L. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression Am J Obstet Gynecol 190 2004 943 951
10. Anderson F.D., Gibbons W., and Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial Am J Obstet Gynecol 195 2006 92 96
11. Anderson F.D., Hait H., Hsiu J., Thompson-Graves A.L., Wilborn W.H., and Williams R.F. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen Contraception 71 2005 55 59
12. Back D.J., Bates M., and Breckenridge A.M. The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette Contraception 23 1981 229 239
13. Fotherby K., Akpoviroro J., and Abdel-Rahman H.A. Pharmacokinetics of ethynyloestradiol in women for different populations Contraception 23 1981 487 496
14. Goldzieher J.W., Dozier T.S., and de la Pena A. Plasma levels and pharmacokinetics of ethynyl estrogens in various populations: II. Mestranol Contraception 21 1980 17 27 (Pubitemid 10129514)
15. Orme M.L., Back D.J., and Breckenridge A.M. Clinical pharmacokinetics of oral contraceptive steroids Clin Pharmacokinet 8 1983 95 136
16. Carol W., Klinger G., and Jager R. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations Exp Clin Endocrinol 99 1992 12 17
17. Endrikat J., Blode H., Gerlinger C., Rosenbaum P., and Kuhnz W. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel Eur J Contracept Reprod Health Care 7 2002 79 90
18. Kuhnz W., al-Yacoub G., and Fuhrmeister A. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation Contraception 46 1992 455 469
19. Back D.J., Grimmer S.F.M., Rogers S., Stevenson P.J., and Orme M.L.E. Comparative pharmacokinetics of levonorgestrel and ethinylestradiol following intravenous, oral, and vaginal administration Contraception 36 1987 471 479
20. Goebelsmann U., Hoffman D., Chiang S., and Woutersz T. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive Contraception 34 1986 341 351
21. Lybrel® Current US Prescribing Information 2010 Wyeth Pharmaceuticals Philadelphia (PA)
22. Data on File. Teva Women's Health Research, Inc.
23. Anderson F.D., Feldman R., and Reape K.Z. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo Contraception 77 2008 91 96
24. Davis M.R., Reape K.Z., and Hait H. Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo Contraception 76 Abstract 42 2007 172